Disposition of flavonoids via enteric recycling: Enzyme-transporter coupling affects metabolism of biochanin A and formononetin and excretion of their phase II conjugates

被引:91
作者
Jia, XB [1 ]
Chen, J [1 ]
Lin, HM [1 ]
Hu, M [1 ]
机构
[1] Washington State Univ, Coll Pharm, Dept Pharmaceut Sci, Pullman, WA 99164 USA
关键词
D O I
10.1124/jpet.104.068403
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The purpose of this study was to continue our effort to determine how enzyme-transporter coupling affect disposition of flavonoids. The rat intestinal perfusion and Caco-2 cell models were used together with relevant microsomes. In perfusion model, isoflavone (i.e., formononetin and biochanin A) absorption and subsequent excretion of its metabolites were always site-dependent. Maximal amounts of intestinal and biliary conjugates excreted per 30 min were 31 and 51 nmol for formononetin, more than that for pure biochanin A ( 12 and 20 nmol). When a standardized red clover extract ( biochanin A/formononetin = 10: 7) was used, the results indicated that more metabolites of biochanin A than formononetin were found in the perfusate (36.9 versus 22.8 nmol) and bile ( 78 versus 51 nmol). In metabolism studies, rat intestinal and liver microsomes always glucuronidated biochanin A faster ( p < 0.05) than formononetin, whereas intestinal microsomes glucuronidated both isoflavones faster ( p < 0.05) than liver microsomes. However, rapid metabolism in the microsomes did not translate into more efficient excretion in either the rat perfusion model as shown previously or in the Caco-2 model. In the Caco-2 model, both isoflavones were rapidly absorbed, efficiently conjugated, and the conjugates excreted apically and basolaterally. More formononetin conjugates were excreted than biochanin A when used alone, but much more biochanin A conjugates were found when using the isoflavone mixture. In conclusion, efficiency of enzyme-transporter coupling controls the amounts of metabolites excreted by the intestine and liver and determines the relative contribution of enteric and enterohepatic recycling to the in vivo disposition of isoflavones.
引用
收藏
页码:1103 / 1113
页数:11
相关论文
共 35 条
[1]  
Baber R J, 1999, Climacteric, V2, P85, DOI 10.3109/13697139909025571
[2]   Dietary agents in cancer prevention: flavonoids and isoflavonoids [J].
Birt, DF ;
Hendrich, S ;
Wang, WQ .
PHARMACOLOGY & THERAPEUTICS, 2001, 90 (2-3) :157-177
[3]   Clinical characteristics and pharmacokinetics of purified soy isoflavones: single-dose administration to healthy men [J].
Busby, MG ;
Jeffcoat, AR ;
Bloedon, LT ;
Koch, MA ;
Black, T ;
Dix, KJ ;
Heizer, WD ;
Thomas, BF ;
Hill, JM ;
Crowell, JA ;
Zeisel, SH .
AMERICAN JOURNAL OF CLINICAL NUTRITION, 2002, 75 (01) :126-136
[4]   Metabolism of flavonoids via enteric recycling: Role of intestinal disposition [J].
Chen, J ;
Lin, HM ;
Hu, M .
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 2003, 304 (03) :1228-1235
[5]   Absorption of quercetin-3-glucoside and quercetin-4′-glucoside in the rat small intestine:: the role of lactase phlorizin hydrolase and the sodium-dependent glucose transporter [J].
Day, AJ ;
Gee, JM ;
DuPont, MS ;
Johnson, IT ;
Williamson, G .
BIOCHEMICAL PHARMACOLOGY, 2003, 65 (07) :1199-1206
[6]   Determination of isoflavone glucoside malonates in Trifolium pratense L. (red clover) extracts:: quantification and stability studies [J].
de Rijke, E ;
Zafra-Gómez, A ;
Ariese, F ;
Brinkman, UAT ;
Gooijer, C .
JOURNAL OF CHROMATOGRAPHY A, 2001, 932 (1-2) :55-64
[7]   MECHANISMS OF TRANSPORT OF QUINAPRIL IN CACO-2 CELL MONOLAYERS - COMPARISON WITH CEPHALEXIN [J].
HU, M ;
ZHENG, LX ;
CHEN, JY ;
LIU, LJ ;
ZHU, YP ;
DANTZIG, AH ;
STRATFORD, RE .
PHARMACEUTICAL RESEARCH, 1995, 12 (08) :1120-1125
[8]   Metabolism of flavonoids via enteric recycling: Mechanistic studies of disposition of apigenin in the Caco-2 cell culture model [J].
Hu, M ;
Chen, J ;
Lin, HM .
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 2003, 307 (01) :314-321
[9]   Identification of CYP1A2 as the main isoform for the phase I hydroxylated metabolism of genistein and a prodrug converting enzyme of methylated isoflavones [J].
Hu, M ;
Krausz, K ;
Chen, J ;
Ge, X ;
Li, JQ ;
Gelboin, HL ;
Gonzalez, FJ .
DRUG METABOLISM AND DISPOSITION, 2003, 31 (07) :924-931
[10]   THE CACO-2 CELL MONOLAYERS AS AN INTESTINAL METABOLISM MODEL - METABOLISM OF DIPEPTIDE PHE-PRO [J].
HU, M ;
CHEN, J ;
TRAN, D ;
ZHU, Y ;
LEONARDO, G .
JOURNAL OF DRUG TARGETING, 1994, 2 (01) :79-89